Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Dec 16:14:3855-3863.
doi: 10.2147/JPR.S340390. eCollection 2021.

Botulinum Toxin Type A for Diabetic Peripheral Neuropathy Pain: A Systematic Review and Meta-Analysis

Chengbing Wang  1 , Qian Zhang  2 , Renjie Wang  3 , Lei Xu  1
Affiliations
Review

Botulinum Toxin Type A for Diabetic Peripheral Neuropathy Pain: A Systematic Review and Meta-Analysis

Chengbing Wang et al. J Pain Res. .

Abstract

Purpose: Botulinum toxin type A (BTX-A) has been proposed as a treatment for painful diabetic peripheral neuropathy (DPN). This systematic review and meta-analysis aimed to assess the effect and safety of BTX-A for treating DPN pain.

Methods: PubMed, Embase, and Cochrane Library were searched for relevant articles published up to July 7, 2021. Randomized clinical trials (RCTs) were included if they were related to the treatment of DPN pain with BTX-A. The primary outcome was the change in intensity of pain and secondary outcomes were adverse effects and changes in sleep and life quality.

Results: A total of four studies, comprising 231 patients, were included in our systematic review. BTX-A treatment induced a greater reduction in the visual analog scale score (mean difference = -2.52, 95% confidence interval [CI] [-3.06, -1.99], p < 0.001) than did the placebo treatment, with no significant heterogeneity between studies (I2 = 0). BTX-A treatment improved several neuropathy pain scale items (eg, hot sensation, sensitive sensation, unpleasant sensation, deep pain, and surface pain) significantly more than with placebo treatment (p < 0.05 for all). There was no significant difference in adverse effect (relative risk = 1.00, 95% CI [0.97, 1.03], p = 0.89).

Conclusion: Intradermal BTX-A injection was shown to be effective and safe in relieving DPN pain. Further larger scale and well-designed RCTs are needed.

Keywords: botulinum toxin; diabetes; peripheral neuropathic pain; systematic review.

PubMed Disclaimer

Conflict of interest statement

The authors report no conflicts of interest in this work.

Figures

Figure 1
Figure 1
Study selection flow diagram.
Figure 2
Figure 2
Quality assessment.
Figure 3
Figure 3
Funnel plot.
Figure 4
Figure 4
Meta-analysis of change in visual analog scale (VAS) score following treatment with botulinum toxin type A (BTX-A) for diabetic peripheral neuropathy (DPN) pain.
Figure 5
Figure 5
Subgroup analysis of change in visual analog scale (VAS) score following treatment with botulinum toxin type A (BTX-A) for diabetic peripheral neuropathy (DPN) pain.
Figure 6
Figure 6
Meta-analysis of change in neuropathy pain scale (NPS) score following treatment with botulinum toxin type A (BTX-A) for diabetic peripheral neuropathy (DPN) pain.
Figure 7
Figure 7
Meta-analysis of the occurrence of adverse effects following treatment with botulinum toxin type A (BTX-A) for diabetic peripheral neuropathy (DPN) pain.
See this image and copyright information in PMC

References

    1. Tankisi H, Pugdahl K, Fuglsang-Frederiksen A, et al. Pathophysiology inferred from electrodiagnostic nerve tests and classification of polyneuropathies. Suggested guidelines. Clin Neurophysiol. 2005;116(7):1571–1580. doi:10.1016/j.clinph.2005.04.003 - DOI - PubMed
    1. Davies M, Brophy S, Williams R, Taylor A. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care. 2006;29(7):1518–1522. doi:10.2337/dc05-2228 - DOI - PubMed
    1. Boulton AJ, Kirsner RS, Vileikyte L. Clinical practice. Neuropathic diabetic foot ulcers. N Engl J Med. 2004;351(1):48–55. doi:10.1056/NEJMcp032966 - DOI - PubMed
    1. Griebeler ML, Morey-Vargas OL, Brito JP, et al. Pharmacologic interventions for painful diabetic neuropathy: an umbrella systematic review and comparative effectiveness network meta-analysis. Ann Intern Med. 2014;161(9):639–649. doi:10.7326/M14-0511 - DOI - PubMed
    1. Rosenberg CJ, Watson JC. Treatment of painful diabetic peripheral neuropathy. Prosthet Orthot Int. 2015;39(1):17–28. doi:10.1177/0309364614542266 - DOI - PubMed

LinkOut - more resources